Ghent University Academic Bibliography

Your filters: cql: author="Roos, Izanne" or (type any "bookEditor issueEditor" and editor="Roos, Izanne")

Add to list
- Journal Article
- A1
- open access
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Izanne Roos, Sifat Sharmin, Charles Malpas, Serkan Ozakbas, Jeannette Lechner-Scott, Suzanne Hodgkinson, Raed Alroughani, Sara Eichau Madueño, Cavit Boz, Anneke van der Walt, et al.

(2024) MULTIPLE SCLEROSIS JOURNAL. 30(9). p.1163-1175
Add to list
- Journal Article
- A1
- open access
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

Anoushka P. Lal, Yi Chao Foong, Paul G. Sanfilippo, Tim Spelman, Louise Rath, David Levitz, Marzena Fabis-Pedrini, Matteo Foschi, Mario Habek, Tomas Kalincik, et al.

(2024) JOURNAL OF NEUROLOGY. 271. p.5813-5824
Add to list
- Journal Article
- A1
- open access
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis : a longitudinal analysis of global and national registries

Sifat Sharmin, Izanne Roos, Charles B Malpas, Pietro Iaffaldano, Marta Simone, Massimo Filippi, Eva Kubala Havrdova, Serkan Ozakbas, Vincenzo Brescia Morra, Raed Alroughani, et al.

(2024) LANCET CHILD & ADOLESCENT HEALTH. 8(5). p.348-357
Add to list
Comparative effectiveness in multiple sclerosis : a methodological comparison

Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, et al.

(2023) MULTIPLE SCLEROSIS JOURNAL. 29(3). p.326-332
Add to list
- Journal Article
- A1
- open access
Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis

Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S. Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, et al.

(2023) JAMA NEUROLOGY. 80(7). p.702-713
Add to list
- Journal Article
- A1
- open access
Disability accrual in primary and secondary progressive multiple sclerosis

Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B Malpas, Ibrahima Diouf, Nahid Moradi, Sifat Sharmin, Guillermo Izquierdo, Sara Eichau, Francesco Patti, et al.

(2023) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 94(9). p.707-717
Add to list
- Journal Article
- A1
- open access
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Ibrahima Diouf, Charles B. Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, et al.

(2023) EUROPEAN JOURNAL OF NEUROLOGY. 30(4). p.1014-1024
Add to list
- Journal Article
- A1
- open access
Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis

Izanne Roos, Stella Hughes, Gavin McDonnell, Charles B. Malpas, Sifat Sharmin, Cavit Boz, Raed Alroughani, Serkan Ozakbas, Katherine Buzzard, Olga Skibina, et al.

(2023) JAMA NEUROLOGY. 80(8). p.789-797
Add to list
- Journal Article
- A1
- open access
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Sifat Sharmin, Izanne Roos, Steve Simpson-Yap, Charles Malpas, Marina M Sánchez, Serkan Ozakbas, Dana Horakova, Eva K Havrdova, Francesco Patti, Raed Alroughani, et al.

(2023) BRAIN. 146(11). p.4633-4644

Academic Bibliography

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis : a longitudinal analysis of global and national registries

Comparative effectiveness in multiple sclerosis : a methodological comparison

Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis

Disability accrual in primary and secondary progressive multiple sclerosis

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Contents

Support

Contact